Product Pipeline
Our pipeline includes preclinical and clinical-stage small-molecule drugs that intervene directly with selected molecular targets in pathways of interest in cardiovascular and metabolic disease.
In September 2011 Madrigal Pharmaceuticals, Inc. (http://www.madrigalpharma.com) acquired the assets of VIA Pharmaceuticals